ProShares UltraShort Nasdaq Biotechnology (BIS)

The ProShares UltraShort Nasdaq Biotechnology (NASDAQ: BIS) is a 2x leveraged inverse ETF that moves opposite the Nasdaq Biotechnology Index with double daily amplitude. When biotech falls 1 percent, BIS aims to rise 2 percent; when biotech rises, BIS falls twice as much. It is a tactical hedging tool and a leveraged bearish bet, not a long-term holding.

The short-exposure mechanism

BIS does not hold biotech stocks. Instead, it maintains short exposure through derivatives—futures contracts and swaps replicating a short position in the Nasdaq Biotechnology Index, amplified 2x. That amplification is reset daily.

The daily reset creates mathematical drag. If biotech rises 2 percent, then falls 2 percent (ending flat), BIS falls 4 percent on day one, then rises 4 percent from a smaller base on day two, netting a loss even though the index ended flat. This is volatility decay—the structural cost of inverse funds held beyond days.

Tactical hedging use cases

BIS serves three narrow purposes. A biotech portfolio manager hedging a long position might short BIS for days or weeks around regulatory risk. A trader betting on near-term biotech weakness might use BIS for 2x exposure without managing a margin account. A volatility trader might use BIS within a spread trade targeting specific price movements.

Beyond those tactical windows, BIS is a drag. An investor holding BIS for months as a hedge against long biotech exposure should instead sell part of the long position or buy put-option protection. Both achieve downside protection without daily decay eroding value.

Cost structure: explicit fees and invisible decay

The expense ratio is roughly 0.95 percent annually—higher than the base biotech ETF—covering derivatives management, daily rebalancing, and operations. That is the visible cost.

The invisible cost is volatility decay. In calm markets (0.5–1 percent daily moves), decay is modest—perhaps 1–2 percent annually even if the index drifts sideways. In stressed markets (2–3 percent daily swings), decay becomes vicious. Each whipsaw amplifies the loss because leverage resets against a shrinking base.

Sponsor and liquidity mechanics

ProShares (owned by Nasdaq) sponsors BIS as a US-registered ETF. The SEC oversees it as a standard ETF, though with explicit warnings about holding-period traps. BIS trades with tight bid-ask spreads during normal hours on the NASDAQ, essential for its tactical role. Liquidity tightens during volatility spikes—precisely when a hedger might want to exit quickly.

The underlying universe

BIS shorts the Nasdaq Biotechnology Index—roughly 150 publicly listed biotech and biopharmaceutical companies, market-cap weighted. Large-cap names (Novo Nordisk, Regeneron, others) dominate. The index concentrates 20–30 percent in its five largest holdings.

When BIS rises, biotech is falling—whether from sector-specific shocks (FDA disappointments, trial failures, reimbursement cuts) or economy-wide stresses (rising rates, flight to safety, recession). BIS is indifferent to the cause; it profits from the direction.

The holding-period trap

Treating BIS as a long-term position is the cardinal mistake. A six-month hedge on a long biotech portfolio via short BIS will leak 3–6 percent to decay even if the index ends flat. A one-year BIS holding in a strong biotech bull market (up 30 percent) will crater 40–50 percent or worse because daily gains compound just as brutally against the short as they do for long positions.

Researching and testing fit

Read the prospectus for daily reset mechanics and short-exposure reconstitution. Check the fund’s fact sheet for current expense ratio and the biotech index’s recent volatility. Backtest: compare BIS’s monthly return to negative twice the index return. If BIS beats that (is less negative), decay is modest and you may have a tactical hedge window. If BIS trails significantly, volatility is high and holding costs money daily.

Use BIS only for days-to-weeks tactical hedging. For longer protection, replace it with a simpler strategy—sell some long biotech or buy put options—that does not bleed on every market move.